This site is intended for healthcare professionals

Phase II and III clinical trials of Tepezza shows reduction in proptosis in thyroid eye disease.- Horizon Therapeutics

Read time: 1 mins
Published:1st Apr 2020
Condition: Thyroid Eye Disease
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest